MapLight Therapeutics (MPLT) Shares Outstanding (Weighted Average) (2024 - 2025)
MapLight Therapeutics recorded quarterly Shares Outstanding (Weighted Average) of $8.7 million in Q4 2025, up 1024.4% quarter-over-quarter from $772031.0 in Q3 2025, and up 1079.16% year-over-year from $736178.0 in Q4 2024.
MapLight Therapeutics' Shares Outstanding (Weighted Average) history runs 2 years deep, the most recent figure standing at $8.7 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 1079.16% year-over-year to $8.7 million; the TTM figure through Dec 2025 stood at $8.7 million (up 1079.16% YoY), while the FY2025 annual figure was $8.7 million, up 1079.16% from the prior year.
- Shares Outstanding (Weighted Average) came in at $8.7 million for Q4 2025 at MapLight Therapeutics, up from $772031.0 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $8.7 million in Q4 2025 to a low of $728343.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 8.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.68 Mn |
| Sep 30, 2025 | 772,031.00 |
| Dec 31, 2024 | 736,178.00 |
| Sep 30, 2024 | 728,343.00 |